Mualliflar

  • Джурабаева М.Х., Аккиев М.И., Абдугаппаров Ф.Б.

##semicolon##

латент туберкулез инфекцияси, скрининг, иммунодиагностика, Диаскин-тест, химиопрофилактика.

##submission.citations##

1. Мордык А.В., Зверева К.А., Пузырёва Л.В., и др. Латентная туберкулёзная инфекция у детей в очагах туберкулёзной инфекции. Туберкулёз и болезни лёгких. 2021;99(3):15-21.

2. Постановление Президента Республики Узбекистан № ПП-123 от 15 мая 2023 года «О мерах по развитию фтизиатрии и пульмонологической службы на 2023–2026 годы». Ташкент; 2023. 12 с.

3. Слогоцкая Л.В., Сенчихина О.Ю., Никитина Г.В., и др. Чувствительность нового кожного теста Диаскинтест® при диагностике туберкулёзной инфекции у детей и подростков. Туберкулёз и болезни лёгких. 2010;87(6):53-57.

4. Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infectious Diseases. 2014;14:91.

5. Fox GJ, Nhung NV, Sy DN, et al. Household-contact investigation for detection of tuberculosis in Vietnam. New England Journal of Medicine. 2018;378(3):221-229.

6. Frigati LJ, et al. Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review. BMC Infectious Diseases. 2025;25:436.

7. Martinez L, Cords O, Horsburgh CR, et al. The risk of tuberculosis disease among children with latent tuberculosis infection: a systematic review and meta-analysis. The Lancet Respiratory Medicine. 2022;10(9):854-865.

8. Santos JM, et al. Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents. Journal of Infection and Chemotherapy. 2022;28(12): 1645-1653.

9. Seddon JA, et al. Levofloxacin versus placebo for the treatment of latent tuberculosis infection in children exposed to multidrug-resistant tuberculosis: the VQUIN MDR trial. Clinical Infectious Diseases. 2020;71(12):3170-3178.

10. Sinhal S, et al. Comparison of 6 months isoniazid versus 3 months isoniazid–rifampicin therapy for prevention of tuberculosis in children suffering from tuberculosis infection – a randomized controlled trial. Indian Journal of Tuberculosis. 2025;72 (4):489-493.

11. Slogotskaya L, Bogorodskaya E, Ivanova D, Sevostyanova T. Comparative sensitivity of the test with tuberculosis recombinant allergen, containing ESAT6-CFP10 protein, and Mantoux test with 2 TU PPD-L in newly diagnosed tuberculosis children and adolescents in Moscow. PLoS ONE. 2018;13(12): e0208705.

12. Starshinova A, Dovgaliuk I, Korneva N, Yakunova O, Yablonskiy P. The diagnosis of latent tuberculosis infection in children with new immunologic tests. European Respiratory Journal. 2014;44 (Suppl 58):P4795.

13. Volkman T, Muruganandah V, Graham H, Tosif S, Stokes S, Ranganathan S. QuantiFERON Gold-In-Tube for the diagnosis of mycobacterial tuberculosis infection in children under 5 years of age: a systematic review and meta-analysis. PLoS ONE. 2024; 19(1):e0295913.

14. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: WHO; 2022. 184 p.

15. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: WHO; 2018. 96 p. (WHO/CDS/TB/2018.4).

16. World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024. 68 p.